Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRILAFON vs STELAZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
Schizophrenia,Schizoaffective disorder,Severe nausea and vomiting (in adults),Bipolar disorder (off-label)
Schizophrenia,Short-term treatment of generalized non-psychotic anxiety (off-label)
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Extensively metabolized in the liver via glucuronidation, sulfoxidation, side-chain oxidation, and N-dealkylation. CYP2D6 is a major enzyme involved in metabolism; polymorphisms can lead to poor metabolizer status.
Hepatic via CYP450 enzymes (primarily CYP2D6); also undergoes N-demethylation and sulfoxidation.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
92-97% bound to albumin and alpha-1 acid glycoprotein.
Approximately 10–15 L/kg; large Vd indicates extensive tissue distribution.
Approximately 18-30 L/kg (0.5-1.5 L/kg). Clinical meaning: Extensive tissue distribution with high CNS penetration.
Oral: 40–50% (due to first-pass metabolism); IM: 100% (assumed complete absorption).
Oral: ~40% (due to first-pass metabolism); IM: 100%.
No dosage adjustment required for GFR 10-50 m L/min; use 50% of normal dose if GFR <10 m L/min.
No specific dose adjustment recommended; use caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use or reduce dose by 75%.
Not recommended for children under 12 years; for ages 12 and older, 6-12 mg orally 2-3 times daily; maximum 24 mg/day.
Children 6-12 years: 1 mg 1-2 times daily; increase gradually up to 15 mg/day. Children >12 years: adult dosing.
Initiate at 4-8 mg orally daily; increase slowly; monitor for QT prolongation, hypotension, and tardive dyskinesia.
Initiate at 1-2 mg twice daily; titrate slowly due to increased sensitivity and risk of orthostatic hypotension and extrapyramidal symptoms.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis.
Extrapyramidal symptoms (including tardive dyskinesia) may occur,Neuroleptic malignant syndrome (NMS) - potentially fatal,QT prolongation and risk of arrhythmias,Orthostatic hypotension,Seizures (lower seizure threshold),Leukopenia, neutropenia, and agranulocytosis,Hematologic toxicity,Hyperprolactinemia,Cognitive and motor impairment,Antiemetic effect may mask signs of toxicity or overdose,Use in elderly with dementia not approved
Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation, leukopenia/neutropenia/agranulocytosis, seizure threshold lowering, anticholinergic effects, hypotension, cholestatic jaundice, ocular changes (corneal/lenticular deposits).
Hypersensitivity to perphenazine or any component of the formulation,Comatose states,CNS depression due to alcohol, barbiturates, or other drugs,Subcortical brain damage,Blood dyscrasias,Bone marrow suppression,Severe hypotension,Known QT prolongation or concurrent use with QT-prolonging drugs
Comatose states, CNS depression (e.g., barbiturates, alcohol), bone marrow depression, blood dyscrasias, hepatic disease, hypersensitivity to phenothiazines.
Avoid grapefruit and grapefruit juice as they may increase perphenazine levels. Limit caffeine intake as it may worsen side effects like restlessness. Taking with food may reduce GI upset but avoid high-fat meals which can affect absorption.
Avoid alcohol and CNS depressants. Grapefruit juice may increase drug levels; avoid concurrent use. Limit caffeine intake. No specific dietary restrictions, but monitor weight gain due to increased appetite.
First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal in neonates after late third trimester exposure. Overall, use only if benefit outweighs risk; avoid during organogenesis.
First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimesters: Risk of extrapyramidal symptoms, jaundice, and hyperreflexia in neonates with late exposure. Case reports of neonatal withdrawal and EPS. Not a known major teratogen but use only if benefits outweigh risks.
Trilafon (perphenazine) is excreted into human milk in small amounts; M/P ratio unknown. Monitor infant for drowsiness, irritability, or movement disorders. Use with caution during breastfeeding.
Excreted in breast milk in small amounts; relative infant dose est. ~0.1-0.5% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, EPS, and poor feeding. Generally considered compatible with breastfeeding with caution.
No established dose adjustment per se; start at lowest effective dose. Increased plasma volume and metabolism during pregnancy may require dose increases to maintain efficacy; individualize based on response and tolerability.
Increased clearance in pregnancy may necessitate dose titration. Start at low end of dosing range; increase gradually based on response and tolerability. Monitor for relapse. Postpartum dose may need reduction due to restored clearance. No specific PK studies available; clinical judgment advised.
TRILAFON (perphenazine) is a typical antipsychotic with potent antiemetic properties. Monitor for extrapyramidal symptoms (EPS), especially akathisia and dystonia. Avoid use in patients with CNS depression or bone marrow suppression. May lower seizure threshold; use cautiously in epilepsy. QT prolongation risk requires ECG monitoring. Taper dose when discontinuing to avoid withdrawal dyskinesias.
Extrapyramidal symptoms (EPS) are common; use benztropine prophylactically in young males. Monitor for QT prolongation, especially in elderly. Avoid in patients with history of tardive dyskinesia. Can cause orthostatic hypotension; titrate slowly. Neuroleptic malignant syndrome (NMS) rare but serious; discontinue immediately if hyperthermia, rigidity, autonomic instability occur.
Avoid alcohol and other CNS depressants.,Report any involuntary muscle movements, stiffness, or restlessness immediately.,May cause drowsiness; avoid driving until you know how the medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Use sun protection as this drug may increase sensitivity to sunlight.,Do not stop taking abruptly without consulting your doctor.,Inform all healthcare providers that you are taking this medication.
Take exactly as prescribed; do not stop abruptly.,May cause dizziness upon standing; rise slowly from sitting or lying down.,Report any involuntary muscle movements, stiffness, or tremors to your doctor.,Avoid alcohol and other central nervous system depressants.,May cause drowsiness; use caution when driving or operating machinery.,Notify your doctor if you experience rapid heartbeat, fainting, or fever with muscle rigidity.,Avoid exposure to extreme heat (can impair body temperature regulation).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRILAFON vs STELAZINE, answered by our medical review team.
TRILAFON is a Phenothiazine Antipsychotic that works by Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.. STELAZINE is a Phenothiazine Antipsychotic that works by Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRILAFON and STELAZINE depend on the specific clinical indication. These are both Phenothiazine Antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRILAFON is: 8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.. The standard adult dose of STELAZINE is: Adults: 2-10 mg orally twice daily; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRILAFON and STELAZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRILAFON is classified as Category C. First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or with. STELAZINE is classified as Category C. First trimester: Limited data; possible increased risk of congenital malformations (neural tube defects, cardiovascular) based on some retrospective studies. Second/third trimester. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.